References for Chapter 9
The Renin-Angiotensin Axis

Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers

Domenic A. Sica, MD
Todd W. B. Gehr, MD
William H. Frishman, MD


18. Burnier M: Angiotensin II type 1-receptor block-
References to Chapter 9

73. Zisman RM: Angiotensin-converting enzyme in-


128. Laeis P, Puchler K, Kirch W: The pharmacokinetic and metabolic profile of olmesartan medoxomil


156. Sica DA, Shaw WC, Lo MW et al: The pharmacoki-


1998.


204. Sica DA. Do pleiotropic effects of antihypertensive medications exist or is it all about the blood pressure? *Curr Hypertens Rep* 10:415, 2008.


209. Gradman AH. Role of angiotensin II type 1 recep-


235. DeQuattro V, Lee D: Fixed-dose combination ther-


352. Massie BM, Carson PE, McMurray JJ, et al. Irbe-


375. Garg S, Narula J, Marelli C, Cesario D: Role of an-
ripgensin receptor blockers in the prevention and

376. Chrysant SG, Chrysant GS: The pleiotropic effects of

of atrial fibrillation by renin-angiotensin system in-

377. Salehian O, Healey J, Stambler B, et al on behalf of
the HOPE Investigators: Impact of ramipril on the
incidence of atrial fibrillation: results of the Heart Outcomes

378. GISSI-AF Investigators: Valsartan for prevention of

379. Chaturvedi N, Porta M, Klein R, et al for the DI-
RECT Programme study group: Effect of candes-
sartan on prevention (DIRECT-Prevent 1) and
progression (DIRECT-Protect 1) of retinopathy in
type 1 diabetes: randomised, placebo-controlled

Programme study group: Effect of candesartan on
progression and regression of retinopathy in type 2
diabetes (DIRECT-Protect 2): a randomised, place-

380a. The Navigator Study Group: Effect of valsartan on the incidence of diabetes and cardiovascular

381. Habashi JP, Judge DP, Holm TM, et al: Losartan,
an AT1 antagonist prevents aortic aneurysm in a


383. The SOLVD investigators: Effect of enalapril on
survival in patients with reduced left ventricular
ejection fractions and congestive heart failure. N


385. Larbre JP, Nicolas JF, Collet P, et al: Kaposi’s sar-
coma in a patient with rheumatoid arthritis poss-
sible responsibility of captopril in the development of

386. Vogt B, Frey FJ: Inhibition of angiogenesis in Ka-

387. Meier CR, Derby LE, Jick SS, Jick H: Angioten-
sin-converting enzyme inhibitors, calcium channel

blockers, ACE inhibitors, and the risk of cancer
in hypertensive patients: A report from the De-
partment of Health Hypertension Care Computing

389. Pahor M, Guralnik JM, Salive ME, et al: Do cal-

390. Lever AF, Hole DJ, Gillis CR, et al: Do inhibitors of
angiotensin-I-converting enzyme protect against

391. Sorensen HT, Mellemkjæer L, et al: Angiotensin-
converting enzyme inhibitors and the risk of can-
cer: A population-based cohort study in Denmark.

392. Friis S, Felmenden DC, Lip GY: Antihypertensive
therapy and cancer risk. Drug Saf 24:727–739,

393. Rosenthal T, Gavras I. Angiotensin inhibition and
malignancies: a review. J Hum Hypertens 23:623,
2009.

393a. Sipahi I, Debanne SM, Rowland DY, et al: Angio-
tensin receptor blockade and risk of cancer: meta-
analysis of randomised controlled trials. Lancet

394. Textor SC: Renal failure related to angiotensin-

395. Textor SC, Bravo EL, Fouad FM, Tarazi RC: Hyper-
kalemia in azotemic patients during angiotensin-
converting enzyme inhibition and aldosterone

396. Garcia NH, Baigorria ST, Juncos LI: Hyperkalemia,
renal failure, and converting-enzyme inhibition:
An overrated connection. Hypertension 38:639,

397. Bakris GL, Siomos M, Richardson D, et al: ACE in-
hibition or angiotensin receptor blockade: impact
on potassium in renal failure. VAL-K Study Group.

398. Griffing GT, Sandler BH, Aurecchia SA, Melby JC:
Reversal of diuretic-induced secondary hyperaldo-
steronism and hypokalemia by enalapril (MK-421):
A new angiotensin-converting enzyme inhibitor.
Metabolism 32:711, 1983.

399. Israili ZH, Hall WD: Cough and angioneurotic
associated with angiotensin-converting enzyme
inhibitor therapy: A review of the literature and

400. Chalmers D, Dombey SL, Lawson DH: Post-mar-
teting surveillance of captopril (for hypertension):


References to Chapter 9 9-17